Literature DB >> 8439518

Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue.

M Isogai1, H Shimizu, Y Esumi, T Terasawa, T Okada, K Sugeno.   

Abstract

The binding affinities of mometasone furoate (MF), its metabolites and related compounds for the glucocorticoid receptor of rat epidermis and dermis were measured. MF and its main metabolite exhibited binding affinities higher than those of alclomethasone dipropionate (ADP) and betamethasone dipropionate (BDP), but equivalent to betamethasone 17-valerate (BMV). For compound I (metabolite of MF), ADP, BDP and BMV, the binding affinity was found to be higher in epidermis relative to dermis. This difference in the dermal/epidermal binding ratio may be a favorable sign leading to a possible reduction of dermal collagen atrophy, a known side effect of glucocorticoids. In structure-binding relationship studies, esterification of the 17-OH by furoylation and introduction of the 9 alpha-Cl caused a marked increase of the binding affinity, whereas the 6 beta-hydroxylation led to a pronounced decrease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8439518     DOI: 10.1016/0960-0760(93)90021-n

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  6 in total

Review 1.  Safety of inhaled and intranasal corticosteroids: lessons for the new millennium.

Authors:  B J Lipworth; C M Jackson
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

Review 2.  Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept.

Authors:  M Schäfer-Korting; M H Schmid; H C Korting
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

3.  Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate.

Authors:  Zia R Tayab; Tom C Fardon; Daniel K C Lee; Kay Haggart; Lesley C McFarlane; Brian J Lipworth; Günther Hochhaus
Journal:  Br J Clin Pharmacol       Date:  2007-05-17       Impact factor: 4.335

Review 4.  Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders.

Authors:  A Prakash; P Benfield
Journal:  Drugs       Date:  1998-01       Impact factor: 11.431

5.  Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate.

Authors:  Anagnostis Valotis; Petra Högger
Journal:  Respir Res       Date:  2007-07-25

6.  Significant receptor affinities of metabolites and a degradation product of mometasone furoate.

Authors:  Anagnostis Valotis; Petra Högger
Journal:  Respir Res       Date:  2004-07-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.